Truvian Recruits Biotech Entrepreneur for Chief Medical and Strategy Officer Job

Truvian Health has appointed Michael J. Mina, M.D., Ph.D., as chief medical and strategy officer. A former Harvard professor and a globally recognized leader in epidemiology and diagnostic technology, Dr. Mina joins the company as it accelerates its mission to decentralize blood testing following the recent U.S. Food and Drug Administration (FDA) clearance of its TruVerus, a multimodal blood analyzer.

In his new role with Truvian, Dr. Mina will oversee clinical and regulatory strategy while advancing strategic partnerships and opportunities across the biomedical and technology sector to accelerate Truvian’s market adoption and growth.

Dr. Mina’s career has been defined by his work at the intersection of immunology, diagnostics, bioengineering, and public health. A former professor at the Harvard T.H. Chan School of Public Health and Harvard Medical School, his research has fundamentally shaped aspects of the modern understanding of the role diagnostics play in disease prevention and health system innovation. During the COVID-19 pandemic, Dr. Mina emerged as a leading global voice on testing strategy, advising governments and industry leaders on ways to use technology to build more resilient health systems.

“We are entering a pivotal chapter at Truvian as we move toward commercialization of the TruVerus platform,” Truvian Co-Founder/Chief Operating Officer Dena Marrinucci, Ph.D., stated. “Dr. Mina’s unique perspective as both a clinician and a technologist is a perfect match for our culture of rigorous science and accessibility. His track record of bridging the gap between academic discovery and practical, large-scale deployment will be invaluable as we work to place lab-quality diagnostics directly into the hands of healthcare providers wherever care happens.”

Before joining Truvian, Dr. Mina was the associate director of molecular diagnostics at Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard. In addition to his clinical and academic contributions, he is a seasoned entrepreneur, having helped lead and exit numerous biotechnology companies and is a lecturer at the MIT Sloan School of Management. His expertise in commercializing next-generation diagnostic technologies, including digital health platforms that link testing with telemedicine, aligns with Truvian’s mission to decentralize the traditional lab model.

“Truvian is doing what many thought was impossible: miniaturizing and automating the gold standard of lab testing without compromising on accuracy,” Dr. Mina said. “Throughout my career, I have advocated for diagnostics that are not just precise, but also more accessible to more people and that can offer results when we need them most—at the point of care. Truvian is doing just that and I am thrilled to join Dena and the entire Truvian team to help realize a future where diagnostic data empowers providers to deliver faster, more informed care with results available in minutes, all towards building a more resilient healthcare system.”

Truvian Health is a diagnostics company redefining healthcare through its FDA-cleared, multimodal blood testing platform. Built on a foundation of scientific integrity and innovation, Truvian empowers providers and patients with convenient, accurate, timely, and comprehensive testing without compromise. Truvian’s assays deliver central lab‑quality results available to anyone, anywhere.